Preparing for Market: Reimbursement Strategies for Cell and Gene Therapies
Published 08 September 2017
In this interview with Regulatory Focus, Ted Slocomb and Michael Werner, two leaders from the Alliance for Regenerative Medicine (ARM), provide insight into future challenges and opportunities for ensuring market access and value-based reimbursement for gene and cell therapies.
Categories: Features, US, FDA, Biologics and biotechnology, Human cell and tissue, Reimbursement
Tags: Regenerative Medicine, ARM, Michael Werner, Ted Slocomb